Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.
CITATION STYLE
Marín V., A., Gazmuri B., J. T., Andresen V., M., & Andresen, M. (2015). Terapia trombolítica en TEP submasivo/riesgo intermedio: Evidencias y sugerencias post estudio Pulmonary Embolism Thrombolysis (PEITHO). Revista Medica de Chile, 143(7), 895–904. https://doi.org/10.4067/S0034-98872015000700011
Mendeley helps you to discover research relevant for your work.